In cancer immunotherapy, the target often matters as much as the molecule, and few targets have drawn more development money than BCMA — B-cell maturation antigen, a protein on the surface of the malignant plasma cells that drive multiple myeloma. CAR-T therapies, bispecific antibodies, and antibody-drug conjugates have all been aimed at it. So when a major pharmaceutical company is issued a patent covering antibodies to that target, the grant is a marker of where defensive coverage now sits. The last week of May 2026 produced exactly that for Bristol-Myers Squibb.

On 26 May 2026, the U.S. patent office granted US12637522B2, titled simply "Monoclonal antibodies against BCMA." The abstract is as terse as patents get:

The invention relates to new antibodies against BCMA, their manufacture and use.— Monoclonal antibodies against BCMA, US12637522B2

The brevity hides the commercial weight. The grant's claims reach to bispecific formats — the issued claim text covers "a method for making a bispecific antibody" — which is the construct class behind the T-cell-engaging myeloma therapies that have reshaped treatment of the disease. Its CPC classifications cluster in C07K 16/468 and C07K 16/2878 (antibody structure and the relevant antigen-binding classes) with A61P 35/02 (antineoplastic use against leukemia/lymphoma-type cancers), which confirms the grant is an antibody-against-a-cancer-target claim rather than a small-molecule or formulation matter. For a target as crowded as BCMA, an issued antibody patent is a piece of the freedom-to-operate map that other developers in the space have to read.

It is worth being precise about why BCMA draws this much filing activity. B-cell maturation antigen is expressed almost exclusively on plasma cells, and it is present at high levels on the malignant plasma cells of multiple myeloma — a cancer that, despite a long succession of new drugs, remains incurable and relapses repeatedly, so patients cycle through multiple lines of therapy over years. That combination — a target largely restricted to the diseased cell type, and a disease that keeps coming back and needs new options at each relapse — is what makes BCMA one of the most contested antigens in oncology. Multiple modalities aim at it: CAR-T cell therapies, antibody-drug conjugates, and the T-cell-engaging bispecific antibodies that the new grant's bispecific claims speak to. An issued patent in that arena is a position staked on a target the whole myeloma field keeps returning to, which is why the record is worth a business reader's attention rather than just a scientific one.

The grant sits inside a wide antibody estate

What makes this a coverage map is the footprint around it. BMS's issued patents in immuno-oncology antibodies extend well beyond BCMA, across the checkpoint and co-stimulatory targets that define the field. US10512689B2 covers compositions combining nivolumab and ipilimumab — the company's two foundational checkpoint antibodies, anti-PD-1 and anti-CTLA-4 — as a fixed-dose combination, which is coverage on how the marketed antibodies are paired, not just the antibodies themselves. On the agonist side, US10493140B2 covers anti-ICOS agonist antibodies and US10501550B2 covers antibodies against GITR, both T-cell co-stimulatory targets that companies have chased as the next layer beyond PD-1 blockade.

The estate also reaches into other myeloma and combination antibody approaches. US10494433B2 covers the combination of an anti-KIR antibody with an anti-CS1 antibody to treat multiple myeloma — a second issued myeloma-antibody position alongside the new BCMA grant — and US10519187B2 covers cyclic dinucleotides as anticancer agents, the STING-pathway chemistry that companies have explored as a partner for checkpoint antibodies. BCMA antibodies, checkpoint combinations, agonist antibodies, KIR/CS1 myeloma combinations: the issued footprint reads as layered coverage across the antibody approaches to cancer, with the new grant adding the BCMA tile.

The shape of that footprint is itself informative. It is not a single blockbuster patent surrounded by empty space; it is a set of issued claims distributed across the targets that successive waves of immuno-oncology have prized — the first wave of checkpoint blockade (PD-1, CTLA-4), the co-stimulatory agonists that researchers turned to as a second layer (ICOS, GITR), and the antigen-directed and myeloma-specific approaches (KIR/CS1, and now BCMA). Coverage that tracks the field's own progression, target by target, is what a sustained antibody program produces over time. For a business reader, the practical takeaway is that the value of any one grant is partly a function of the company it keeps: an issued BCMA antibody patent sitting inside an estate that also covers the marketed checkpoint combinations and the next-generation co-stimulatory antibodies represents a broader antibody position than the single document would suggest on its own.

What the issued coverage buys

The business significance of a coverage map like this is in freedom-to-operate. A granted claim is the enforceable part of an estate, and BMS's grants are clustered on the targets and combinations that the whole immuno-oncology field is built around. A developer bringing a competing BCMA antibody, or a novel checkpoint combination, into the clinic has to navigate around issued claims that occupy those positions — which is the kind of pressure that shows up as licensing negotiations, design-arounds, or litigation rather than in any headline. The dates also indicate an estate that keeps refreshing: a 26 May 2026 grant on a target as contested as BCMA shows the company is still converting filings into issued antibody coverage years into the immuno-oncology era.

The caveats are the usual ones for a coverage read. Issued claims describe what was granted, not how broadly a court would construe them or whether any survives a validity challenge — and on a heavily worked target like BCMA, multiple companies hold overlapping antibody patents, so a single grant maps one position rather than the whole field. The older grants cited here reflect filings made years ago, and patent terms run on their own clocks. But the pattern across BMS's issued antibody patents is consistent: coverage concentrated on the targets — BCMA, PD-1, CTLA-4, ICOS, GITR, KIR/CS1 — that anchor cancer immunotherapy. The 26 May 2026 BCMA grant is the newest tile in that map, and it lands on one of the most commercially important targets in myeloma.